A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219

Simply Wall St.

Jan 13

Rapport Therapeutics (RAPP) is back in focus after receiving FDA clearance to start Phase 3 trials of its lead candidate RAP-219 in focal onset seizures, alongside updates across its broader central ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603355196"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603355196\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603355196?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-01-13 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603355196","market":"nz","top_or_hot":-1,"title":"A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219","media":"Simply Wall St.","content":"<div>\n<p>Rapport Therapeutics (RAPP) is back in focus after receiving FDA clearance to start Phase 3 trials of its lead candidate RAP-219 in focal onset seizures, alongside updates across its broader central ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/a-look-at-rapport-therapeutics-rapp-valuation-after-fda-clea\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/a-look-at-rapport-therapeutics-rapp-valuation-after-fda-clea><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rapport Therapeutics (RAPP) is back in focus after receiving FDA clearance to start Phase 3 trials of its lead candidate RAP-219 in focal onset seizures, alongside updates across its broader central ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/a-look-at-rapport-therapeutics-rapp-valuation-after-fda-clea\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAPP","symbol_name":"Rapport Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/a-look-at-rapport-therapeutics-rapp-valuation-after-fda-clea","article_id":"2603355196","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/a-look-at-rapport-therapeutics-rapp-valuation-after-fda-clea","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603355196","pubTimestamp":1768302919,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Rapport Therapeutics (RAPP) is back in focus after receiving FDA clearance to start Phase 3 trials of its lead candidate RAP-219 in focal onset seizures, alongside updates across its broader central nervous system pipeline.\nSee our latest analysis for Rapport Therapeutics.\nDespite the positive FDA update and broader pipeline progress, Rapport Therapeutics’ recent share price performance has been softer, with a 1 month share price return of 10.8% and a 7 day share price return of 2.39%. Its 1...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAPP":"Rapport Therapeutics, Inc.","BK4007":"制药"},"translate_title":"FDA批准RAP-219 3期试验后Rapport Therapeutics(RAPP)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAPP":1.5},"content_text":"Rapport Therapeutics (RAPP) is back in focus after receiving FDA clearance to start Phase 3 trials of its lead candidate RAP-219 in focal onset seizures, alongside updates across its broader central nervous system pipeline. See our latest analysis for Rapport Therapeutics. Despite the positive FDA update and broader pipeline progress, Rapport Therapeutics’ recent share price performance has been softer, with a 1 month share price return of 10.8% and a 7 day share price return of 2.39%. Its 1 year total shareholder return of 112.77% points to longer term momentum that investors are now reassessing at a last close of $27.0. If this kind of biotech catalyst has your attention, it could be a good moment to see which other healthcare stocks are starting to move. Use it to spot fresh ideas beyond your current watchlist. With the stock at $27.0, recent returns softer and analysts pointing to a US$52.25 price target on average, is Rapport Therapeutics now trading below its potential, or is the market already factoring in future growth? AdvertisementPrice-to-Book of 2.5x: Is it justified? On a P/B of 2.5x, Rapport Therapeutics trades slightly below both its US Pharmaceuticals group and a narrower peer set, even with no current revenue. P/B looks at the share price relative to the company’s net assets, which can be a useful reference point for early stage biopharma where profits are still a way off. For a business with US$0 in revenue and a net loss of US$97.7m, P/B effectively indicates how the market is valuing the balance sheet and the underlying pipeline. Here, the 2.5x P/B sits just under the broader US Pharmaceuticals industry average of 2.6x, and well below the peer average of 4.5x. That spread suggests investors are assigning a lower multiple to Rapport’s equity than to comparable names, even with the recent 1 year total shareholder return of 112.77%. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 2.5x (ABOUT RIGHT) However, there are clear risks here, including potential Phase 3 trial setbacks for RAP-219 and ongoing net losses of US$97.7m, which could pressure future funding needs. Find out about the key risks to this Rapport Therapeutics narrative.  Build Your Own Rapport Therapeutics Narrative If you see the data differently or prefer to test your own assumptions, you can build a complete view of Rapport in just a few minutes, starting with Do it your way. A great starting point for your Rapport Therapeutics research is our analysis highlighting 5 important warning signs that could impact your investment decision. Ready for more investment ideas? If you stop your research here, you could miss opportunities that fit your style even better, so use the screeners to broaden your opportunity set.  Spot potential turnaround stories early by scanning these 881 undervalued stocks based on cash flows that the market may not be fully pricing in yet. Tap into the momentum behind artificial intelligence by reviewing these 26 AI penny stocks shaping the next wave of growth in tech. Boost your income focus by checking out these 12 dividend stocks with yields > 3% that might complement higher risk growth names in your portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}